Comparative Pharmacology
Head-to-head clinical analysis: CETIRIZINE HYDROCHLORIDE ALLERGY versus PYRILAMINE MALEATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CETIRIZINE HYDROCHLORIDE ALLERGY versus PYRILAMINE MALEATE.
CETIRIZINE HYDROCHLORIDE ALLERGY vs PYRILAMINE MALEATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cetirizine hydrochloride is a second-generation histamine H1-receptor antagonist. It acts by selectively and reversibly blocking histamine H1 receptors on effector cells (e.g., smooth muscle, endothelial cells, mucous glands), thereby inhibiting histamine-mediated allergic responses such as vasodilation, increased vascular permeability, bronchoconstriction, and itching. It does not prevent histamine release but antagonizes its effects.
Pyrilamine is a first-generation antihistamine that competitively antagonizes histamine at H1 receptors, thereby preventing histamine-mediated effects such as increased vascular permeability, vasodilation, and bronchoconstriction.
5-10 mg orally once daily; maximum 10 mg/day.
25-50 mg orally every 6-8 hours as needed, not to exceed 200 mg per day.
None Documented
None Documented
Terminal elimination half-life: approximately 8-11 hours in healthy adults; increases to ~18-20 hours in elderly (due to decreased renal function); prolonged in renal impairment (CrCl <31 mL/min: up to 20-30 hours)
Approximately 16-23 hours in healthy adults; may be prolonged in elderly or hepatic impairment.
Renal: approximately 70% (60% as unchanged drug, 10% as metabolites); Fecal: approximately 10%; Biliary: negligible
Primarily renal as metabolites; about 80-90% excreted in urine within 24 hours, with less than 5% unchanged; minor biliary/fecal elimination.
Category A/B
Category C
Antihistamine
Antihistamine